Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
Read more
Latest
Novartis Gains First-ever Approval for Infant Malaria Medicine
In a breakthrough for pediatric malaria treatment, Novartis has received approval from Swissmedic for Coartem® (artemether-lumefantrine) Baby, marking the first-ever
Read more
FDA Approves Gilead’s Yeztugo® (Lenacapavir) as First Biannual Injectable HIV PrEP
Gilead Sciences, Inc. (Nasdaq: GILD) has announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) as
Read more
Harbour BioMed and Otsuka to Advance Bispecific T-Cell Engager for Autoimmune Diseases
Harbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read more
Sanofi Acquires Blueprint in $9.1B Deal to Bolster Rare Immunological Disease Pipeline
Sanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read more
Roche Advances Novel Antibiotic Targeting Superbug into Phase 3 Trials
Swiss pharmaceutical company Roche has announced plans to advance its experimental antibiotic, zosurabalpin, into Phase 3 clinical trials. Developed in
Read more
Sanofi Bolsters Alzheimer’s Disease Pipeline with $470M Acquisition of Vigil Neuroscience
Sanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read more
BioMarin Expands Enzyme Therapies Portfolio with Inozyme Acquisition
BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read more
GSK Bolsters Gastrointestinal Cancer Portfolio with $1.15B Acquisition of IDRx
In a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read more
AstraZeneca Unveils $300 Million Cell Therapy Manufacturing Facility in Rockville, USA
Global biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read more